MedTrace Logo

Integrated Analysis of Therapy Response and Resistence in Embryonal Tumors and Gliomas

NCT06323408 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 72

Last updated 2025-03-25

No results posted yet for this study

Summary

The treatment of adolescents and young adults (AYA, 15 to 39 years) with malignant intra-axial CNS parenchymal tumors such as IDH-mutated gliomas, medulloblastomas and ependymomas is still not curative in all cases. The tumor biology and clinical needs to diagnose and treat these tumors are comparable across all age groups, so an integrated treatment environment overseen by adult and pediatric neuro-oncology specialists seems promising to leverage synergisms and advance diagnostic and therapeutic development in these tumors. A comprehensive, prospective and integrated biomaterial and imaging-based pipeline for the multi-faceted evaluation of AYAs has not yet been established for AYA patients with brain tumors in Germany. Current diagnostic platforms neglect the integrative processing of data from MRI and FET-PET imaging, radiotherapy plans, tumor tissue, liquid biopsies and clinical data as well as prognostic markers. A prospective AYA pipeline can therefore enable a better understanding of the aforementioned high-risk CNS malignancies and promises clinical advances for AYA patients and the clinical and scientific research landscape.

Conditions

Interventions

DIAGNOSTIC_TEST

Tissue, blood, cerebrospinal-spinal fluid

Processing, analysis

Sponsors & Collaborators

  • University Hospital Regensburg

    lead OTHER

Principal Investigators

  • Peter Hau, Prof. · University Hospital Regensburg

Eligibility

Min Age
15 Years
Max Age
39 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-05-31
Primary Completion
2025-09-30
Completion
2026-03-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06323408 on ClinicalTrials.gov